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INCIDENCE
The true incidence of peripartum cardiomyopathy 
(PPCM) is unknown. Reported incidence varies 
between 1 in 3000 and 1 in 10 000 pregnancies.
AETIOLOGY AND PATHOPHYSIOLOGY
The aetiology of PPCM is unknown. It is postulated 
that PPCM could be mediated through many mecha-
nisms including immunological factors, an abnormal 
hormone response, abnormal inflammatory changes, 
myocarditis, or a genetic predisposition.
PPCM manifests predominantly as ventricular systolic 
dysfunction from a global reduction in myocardial 
contraction and thus left ventricular ejection fraction. 
Compensation through the enlargement of the left 
ventricle occurs, increasing end-diastolic volume and 
stroke volume. As compensation fails, cardiac output 
falls and cardiac failure ensues.
RISK FACTORS
Risk factors for PPCM include:
• maternal age > 30 years
• multiparity
• ethnic group, e.g. African descent
• obesity
• multiple pregnancy
• pregnancy-associated hypertensive disorders
• essential hypertension
• tocolytic therapy with β-agonists
• cocaine use.
CLINICAL FEATURES AND DIAGNOSIS
Symptoms of shortness of breath on exertion and 
orthopnoea are common in the third trimester. 
Diagnosis of PPCM can be delayed if these symptoms 
are erroneously attributed to the normal physiological 
changes of pregnancy. Symptoms of PPCM include 
dyspnoea, fatigue, orthopnoea, paroxysmal nocturnal 
dyspnoea, palpitations, haemoptysis and peripheral 
oedema. These may present as acute or subacute 
episodes of left ventricular failure.
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Summary
Peripartum cardiomyopathy 
is a rare condition that 
affects women in late 
pregnancy and in the 
postpartum period.
It is characterised by heart 
failure that presents in 
the absence of any other 
identifiable cause.
It is associated with 
significant morbidity and 
mortality.
Early recognition and 
aggressive management of 
the condition is crucial to 
improving outcome.
Example case
• A 37-year-old woman presents at 36 weeks’ 
gestation in her fourth pregnancy with a 
6-day history of worsening shortness of 
breath, paroxysmal nocturnal dyspnoea, 
orthopnoea and peripheral oedema. Her 
three previous pregnancies were unevent-
ful and she delivered vaginally each time.
• Her past medical history includes hypothy-
roidism and morbid obesity (BMI 40). She 
has no known cardiac history. There is no 
familial history of note, and no background 
of drug or significant alcohol consumption.
• On examination the patient is tachypnoeic 
and tachycardic at rest, with normal blood 
pressure. Oxygen saturation is 92% in room 
air. Bibasal coarse crackles are audible on 
auscultation. Arterial blood gas analysis 
reveals a respiratory alkalosis with mild 
hypoxaemia. Electrocardiography (ECG) 
demonstrates sinus tachycardia with left 
bundle branch block and chest X-ray shows 
cardiomegaly with fluid in the horizontal 
fissure and prominent upper lobe vessels.
• Transthoracic echocardiography reveals 
severe left ventricular dysfunction, with 
an ejection fraction of 15–17%, dilated 
cardiomyopathy (left ventricular end-
diastolic diameter 81 mm), severe mitral 
and moderate tricuspid regurgitation with 
moderately elevated pulmonary artery 
pressure.
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Tachyarrhythmias can occur in PPCM, including supraventricular 
tachycardia (SVT), atrial fibrillation (AF) and, rarely, ventricular 
tachycardia (VT). There is an increased risk of thromboembolism 
due to the potential development of mural thrombus.
PPCM is a diagnosis of exclusion. Parturients with recognised con-
genital or acquired heart disease can present with similar symptoms 
in late pregnancy or during labour. Similarly, pregnant women with 
undiagnosed ischaemic or structural heart disease have decreased 
functional reserve and are less able to tolerate the haemodynamic 
physiological changes of normal pregnancy.
Diagnosis of PPCM requires four criteria to be met:1
1. heart failure developing towards the end of pregnancy or up to 
5 months post partum
2. absence of another identifiable cause of cardiac failure
3. absence of cardiac symptoms or disease prior to late pregnancy
4. left ventricular dysfunction – defined as an ejection fraction 
less than 45% or reduced fractional shortening of less than 
30%.
Cardiomyopathy meeting criteria 2–4 but presenting earlier than the 
third trimester is referred to as pregnancy-associated cardiomyopathy 
(PACM). The underlying pathophysiology is probably similar to 
that of PPCM.2
DIFFERENTIAL DIAGNOSES
Differential diagnoses of PPCM include:
• pulmonary embolism
• severe sepsis
• amniotic fluid embolism
• pre-eclampsia/pregnancy-induced hypertensive disease
• arrhythmias
• severe anaemia
• myocardial infarction
• dilated cardiomyopathy of other aetiologies (see Table 1).
INVESTIGATIONS
Investigations include:
• ECG
• transthoracic echocardiography including Doppler studies
• cardiac magnetic resonance imaging
• coronary angiography
• viral studies
• B-type natriuretic peptide (BNP) is a screening marker but lacks 
specificity.
PROGNOSIS
Prognosis is poor and PPCM is one of the leading causes of maternal 
death.3 A prognostic indicator is the degree of dysfunction at 
presentation, defined either by the New York Heart Association 
(NYHA) functional classification or by the findings on transthoracic 
echocardiography.
The mortality rate is between 15% and 50%, while 30–50% will 
improve and recover a left ventricular ejection fraction of 50% or 
more. Death results from intractable heart failure, arrhythmias and 
thromboembolism.
MANAGEMENT
Early identification of PPCM enables optimal management. 
Multidisciplinary management by senior staff is essential, and should 
include involvement from an obstetrician, a cardiologist with a 
special interest in obstetric disorders, and an anaesthetist. Should 
PPCM present during pregnancy, maternal optimisation is key, 
which may necessitation expedited delivery. A neonatologist should 
be involved in discussions regarding timing of delivery and to address 
the potential impact of maternal disease on neonatal outcome. If 
critical care admission is likely, early involvement of a critical care 
specialist is important.
Where women with PPCM should be cared for will depend on the 
timing and presentation of the condition. Referral to a specialist 
obstetric care centre with the expertise and resources to manage such 
patients should be considered in all cases.
Pharmacological therapies
Management of PPCM is similar to that of other causes of cardiac 
failure and includes maintenance of adequate oxygenation, fluid 
Table 1. Causes of dilated cardiomyopathy
Aetiology Examples
Infectious Viral, e.g. coxsackievirus, HIV, Epstein–Barr virus
Bacterial, e.g. Streptococcus, tuberculosis
Haematological Iron deficiency anaemia, sickle cell disease, 
thalassaemia
Endocrine Hypothyroidism, hyperthyroidism, 
phaeochromocytoma
Autoimmune Systemic lupus erythematosus, rheumatoid arthritis
Metabolic Haemochromatosis
Ischaemic Coronary artery disease
Neuromuscular Friedreich’s ataxia, muscular dystrophies
Drugs Alcohol, chemotherapeutic agents, e.g. 
cyclophosphamide
Others Nutrition related, e.g. thiamine deficiency
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and salt restriction and ventricular off-loading by vasodilation and 
diuresis.
Angiotensin-converting enzyme inhibitors (ACE inhibitors) have 
been shown to improve mortality in cardiac failure and are recom-
mended as first-line therapy for the management of PPCM post 
partum. Angiotensin receptor blockers (ARBs) are an alternative for 
those intolerant to the side-effects of ACE inhibitors. ACE inhibitors 
and ARBs are contraindicated during pregnancy because of the risk 
of birth defects. Administration of ACE inhibitors, particularly in 
the second and third trimesters, is associated with increased fetal loss 
and fetal renal dysfunction, oligohydramnios and other congenital 
anomalies. ACE inhibitors and ARBs are not recommended for use 
in breastfeeding mothers initially because of the risk of neonatal 
hypotension.4
Post-partum ACE inhibitor therapy is indicated for as long as the 
left ventricle remains impaired. In the longer term, ACE inhibitor 
therapy may improve cardiac remodelling.
Hydralazine and nitrate therapy, such as isosorbide dinitrate, can be 
used safely during pregnancy. These drugs reduce afterload, preload 
and intracardiac filling pressures. Beta-blockers have been shown to 
improve survival and may be protective against tachyarrhythmias.
Digoxin is considered safe in pregnancy and may be used for its 
positive inotropic effect and for the treatment of atrial fibrillation 
should it occur. Digoxin plasma levels should be carefully monitored.
Loop diuretics, e.g. furosemide, may reduce pulmonary congestion 
and peripheral oedema and can be used safely in pregnancy and 
lactation.
Calcium channel blockers are usually avoided because of their 
negative inotropic properties. Aldosterone antagonists such as 
spironolactone are not recommended during pregnancy.
Endomyocardial biopsy can be performed to assess whether intra-
venous immunoglobulin may be of benefit. There is some evidence 
in small trials to suggest this targeted therapy and others, such as 
bromocriptine and pentoxifylline, may be of benefit if biopsy shows 
an inflammatory component.5–7
Not all PPCM is associated with a myocarditis inflammatory state 
and immunoglobulin therapy is not recommended empirically.
Owing to the risk of venous thromboembolism and mural thrombus 
associated with PPCM, prophylactic low-molecular-weight heparin 
(LMWH) therapy is indicated. If thromboembolic sequelae or mural 
thrombus have been identified, full anticoagulation is indicated.
Non-pharmacological therapies
Patients in the acute setting may need supportive therapy with non-
invasive ventilation or intubation, ventilation and inotropic support.
In severe cases an intra-aortic balloon pump, left ventricular assist 
device (LVAD) or extracorporeal membrane oxygenation (ECMO) 
may be required. Heart transplantation may be indicated for 
patients with severe disease who do not respond to pharmacological 
treatments.
Implantable defibrillators and cardiac resynchronisation are possible 
interventions in those women who survive the acute phase but 
experience on-going significant functional impairment.
Pre-conceptual counselling
Pre-conceptual counselling should be offered to all women with a 
history of PPCM. There is a significant risk of recurrence of PPCM in 
subsequent pregnancies. Women with on-going cardiac impairment 
following PPCM, i.e. NYHA class 3 or 4 cardiac failure, or those 
with a left ventricular ejection fraction of less than 30% are at highest 
risk from further pregnancies.
Women most at risk should be provided with information regarding 
the risks of future pregnancy and guidance on contraception, and 
potential need to consider termination should pregnancy occur.
ANAESTHETIC CONSIDERATIONS
PPCM poses many challenges for the anaesthetist. Anaesthetic 
technique will be influenced by the urgency of delivery and the 
physiological condition of the parturient. Women with suspected 
PPCM, or a past history of PPCM, should be reviewed by an 
anaesthetist in a timely manner and an agreed plan made for labour, 
delivery and postpartum care.
Considerations regarding mode of delivery should include the 
patient’s obstetric history, current haemodynamic status and response 
to medical management. Vaginal delivery is an option for patients 
with compensated PPCM.
Techniques to limit the increase in plasma catecholamines, systemic 
vascular resistance and myocardial workload associated with labour 
are advised.
Aorto-caval compression should be prevented at all times by avoiding 
supine positioning without adequate uterine displacement. Regular 
monitoring with ECG and measurement of oxygen saturation 
and blood pressure should be initiated early with a low threshold 
for invasive arterial blood pressure monitoring. In order to limit 
cardiovascular stress, early labour epidural analgesia is recommended. 
This will not only reduce the sympathetic response caused by painful 
contractions, but also decrease afterload and provide a means of 
achieving surgical anaesthesia should operative intervention be 
required.
The second stage of labour can be managed with instrumental 
assistance, which may reduce myocardial workload and the 
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detrimental cardiovascular effects of prolonged Valsalva manoeuvres 
during pushing.
Both general and regional anaesthesia have been described for 
caesarean delivery.8 Monitoring should include invasive arterial 
blood pressure. Cardiac output monitoring will provide additional 
information that may aid perioperative management.
The anaesthetic management aims are to:
• maintain myocardial perfusion by avoiding:
-	 arrhythmias
-	 episodes of hypotension or tachycardia
• optimise cardiac output
• maintain preload but prevent fluid overload
• maintain/increase myocardial contractility
• prevent increased afterload.
Titrated neuraxial anaesthesia, by incremental top-up of an epidural 
or a combined epidural and low-dose spinal anaesthetic technique, 
may achieve these aims. Neuraxial anaesthesia reduces afterload, 
promoting forward flow, and avoids the use of general anaesthetic 
agents that reduce myocardial contractility. Neuraxial opioids provide 
effective postoperative analgesia, thereby reducing sympathetically 
mediated postpartum increases in afterload. Significant falls in sys-
temic vascular resistance should be avoided so that coronary perfusion 
is maintained. If using a neuraxial anaesthetic technique, attention 
should be given to the timing of anticoagulation administration.
If general anaesthesia is undertaken, induction should be as smooth as 
possible to minimise both hypotension and hypertension. The pressor 
response to laryngoscopy and intubation should be attenuated by 
administration of an appropriate dose of a rapid-acting opioid, e.g. 
alfentanil or remifentanil. Inotropes, such as dobutamine, calcium 
sensitisers (e.g. levosimendan) or phosphodiesterase inhibitors (e.g. 
milrinone) may be necessary to offset the myocardial depression 
of intravenous and volatile anaesthetic agents. Vasopressors may 
also be required to counteract vasodilation and maintain coronary 
perfusion. Preload should be maintained and minimally invasive or 
invasive cardiac output monitoring may provide useful information 
to guide these therapies.
Uterotonic drugs should be used cautiously because of their associated 
side-effects:
• Oxytocin can cause a marked decrease in systemic vascular 
resistance and in higher doses has an antidiuretic effect.
• Ergometrine may cause significant increases in afterload.
Following delivery the patient should be recovered in a critical care 
environment with on-going invasive haemodynamic monitoring, 
careful fluid management and adequate analgesia.
CONCLUSION
• Peripartum cardiomyopathy (PPCM) is a rare condition with 
significant mortality.
• PPCM has strict diagnostic criteria.
• Early identification of PPCM improves outcome.
• Management is multidisciplinary.
• Preconceptual counselling should be offered to women who have 
previously suffered from PPCM.
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